Health
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk for GvHD NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the up
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zvDa2P.MLQrfKYIZ2UPPSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation Award","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Expands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk for GvHD","length":153,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":263,"olType":false},{"type":"text","content":"NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the upcoming initiation of a Phase 1, investigator-sponsored clinical trial evaluating its lead therapy, agenT-797, in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).","length":436,"tagName":"p"},{"type":"text","content":"The trial, led by Hongtao Liu, MD, PhD, Associate Professor of Medicine, University of Wisconsin School of Medicine and Public Health, with co-investigator Kalyan V. G. Nadiminti, MD, Assistant Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, will evaluate the safety, tolerability, and preliminary efficacy of agenT-797 in reducing graft-versus-host disease (GvHD), relapse, and other post-transplant complications in patients with high-risk leukemias and other blood cancers.","length":519,"tagName":"p"},{"type":"text","content":"Two complementary public-private funding awards support the advancement of agenT-797 development in HSCT and GvHD. First, an NIH STTR grant from the National Institute of Allergy and Infectious Diseases (NIAID) supports MiNK and the University of Wisconsin–Madison team to develop and evaluate...